Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06283121 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

StatusNot Yet Recruiting
PhasePhase 2
Started2024-04-02
View on ClinicalTrials.gov ↗

Amendment history

2024-02-27
minor
Study Identification, Study Status v1
Study title-27 characters
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Peritoneal Metastases From Gastric Cancer
2024-02-22
minor
Original filing
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.
Trial Details
NCT Number NCT06283121
Lead Sponsor China Medical University, China
Collaborators: Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Conditions Gastric Cancer, Metastatic
Enrollment 30 participants
Start Date 2024-04-02
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-29